Aclarion (ACON) Competitors

Aclarion logo
$1.34 -0.03 (-2.19%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.36 +0.02 (+1.87%)
As of 11/18/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACON vs. AIFF, ITOC, DRIO, HCTI, and VSEE

Should you buy Aclarion stock or one of its competitors? Aclarion's main competitors and comparable companies include Firefly Neuroscience (AIFF), Itonic (ITOC), DarioHealth (DRIO), Healthcare Triangle (HCTI), and VSee Health (VSEE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Aclarion compare to Firefly Neuroscience?

Aclarion (NASDAQ:ACON) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Aclarion has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, Firefly Neuroscience had 3 more articles in the media than Aclarion. MarketBeat recorded 3 mentions for Firefly Neuroscience and 0 mentions for Aclarion. Firefly Neuroscience's average media sentiment score of 0.65 beat Aclarion's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the news media.

Company Overall Sentiment
Aclarion Neutral
Firefly Neuroscience Positive

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 459.70%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Firefly Neuroscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Firefly Neuroscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Firefly Neuroscience has a net margin of -386.15% compared to Aclarion's net margin of -10,215.15%. Aclarion's return on equity of -62.91% beat Firefly Neuroscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Aclarion-10,215.15% -62.91% -59.33%
Firefly Neuroscience -386.15%-71.97%-59.30%

7.5% of Aclarion shares are held by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aclarion has higher earnings, but lower revenue than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$80K48.24-$7.23M-$5.41N/A
Firefly Neuroscience$2.06M6.81-$19.88M-$0.46N/A

Summary

Aclarion beats Firefly Neuroscience on 9 of the 16 factors compared between the two stocks.

How does Aclarion compare to Itonic?

Itonic (NASDAQ:ITOC) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Itonic has a net margin of 0.00% compared to Aclarion's net margin of -10,215.15%. Itonic's return on equity of 0.00% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
ItonicN/A N/A N/A
Aclarion -10,215.15%-62.91%-59.33%

Itonic has a beta of 3.1, indicating that its stock price is 210% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Aclarion has a consensus target price of $7.50, indicating a potential upside of 459.70%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Itonic.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Itonic
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aclarion
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

7.5% of Aclarion shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Itonic has higher revenue and earnings than Aclarion.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Itonic$520K22.10-$5.10MN/AN/A
Aclarion$80K48.24-$7.23M-$5.41N/A

In the previous week, Itonic's average media sentiment score of 0.00 equaled Aclarion'saverage media sentiment score.

Company Overall Sentiment
Itonic Neutral
Aclarion Neutral

Summary

Itonic and Aclarion tied by winning 6 of the 12 factors compared between the two stocks.

How does Aclarion compare to DarioHealth?

Aclarion (NASDAQ:ACON) and DarioHealth (NASDAQ:DRIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

DarioHealth has a net margin of -159.85% compared to Aclarion's net margin of -10,215.15%. DarioHealth's return on equity of -53.07% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Aclarion-10,215.15% -62.91% -59.33%
DarioHealth -159.85%-53.07%-32.25%

Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, DarioHealth has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

In the previous week, DarioHealth had 12 more articles in the media than Aclarion. MarketBeat recorded 12 mentions for DarioHealth and 0 mentions for Aclarion. DarioHealth's average media sentiment score of 0.11 beat Aclarion's score of 0.00 indicating that DarioHealth is being referred to more favorably in the news media.

Company Overall Sentiment
Aclarion Neutral
DarioHealth Neutral

7.5% of Aclarion shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Comparatively, 3.5% of DarioHealth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aclarion has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$80K48.24-$7.23M-$5.41N/A
DarioHealth$22.36M0.74-$41.71M-$3.90N/A

Aclarion currently has a consensus price target of $7.50, suggesting a potential upside of 459.70%. DarioHealth has a consensus price target of $7.75, suggesting a potential upside of 430.82%. Given Aclarion's higher possible upside, equities research analysts clearly believe Aclarion is more favorable than DarioHealth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
DarioHealth
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

DarioHealth beats Aclarion on 11 of the 15 factors compared between the two stocks.

How does Aclarion compare to Healthcare Triangle?

Aclarion (NASDAQ:ACON) and Healthcare Triangle (NASDAQ:HCTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Aclarion has higher earnings, but lower revenue than Healthcare Triangle. Aclarion is trading at a lower price-to-earnings ratio than Healthcare Triangle, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$80K48.24-$7.23M-$5.41N/A
Healthcare Triangle$13.89M0.21-$9.48M-$670.40N/A

Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, Healthcare Triangle has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Aclarion currently has a consensus target price of $7.50, suggesting a potential upside of 459.70%. Given Aclarion's stronger consensus rating and higher probable upside, equities analysts plainly believe Aclarion is more favorable than Healthcare Triangle.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Healthcare Triangle
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

7.5% of Aclarion shares are held by institutional investors. Comparatively, 0.3% of Healthcare Triangle shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 0.1% of Healthcare Triangle shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Healthcare Triangle has a net margin of -45.37% compared to Aclarion's net margin of -10,215.15%. Healthcare Triangle's return on equity of -54.80% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Aclarion-10,215.15% -62.91% -59.33%
Healthcare Triangle -45.37%-54.80%-22.80%

In the previous week, Healthcare Triangle had 2 more articles in the media than Aclarion. MarketBeat recorded 2 mentions for Healthcare Triangle and 0 mentions for Aclarion. Healthcare Triangle's average media sentiment score of 1.00 beat Aclarion's score of 0.00 indicating that Healthcare Triangle is being referred to more favorably in the news media.

Company Overall Sentiment
Aclarion Neutral
Healthcare Triangle Positive

Summary

Aclarion beats Healthcare Triangle on 8 of the 15 factors compared between the two stocks.

How does Aclarion compare to VSee Health?

Aclarion (NASDAQ:ACON) and VSee Health (NASDAQ:VSEE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Aclarion has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, VSee Health has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 459.70%. Given Aclarion's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aclarion is more favorable than VSee Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
VSee Health
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Aclarion has higher earnings, but lower revenue than VSee Health. Aclarion is trading at a lower price-to-earnings ratio than VSee Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$80K48.24-$7.23M-$5.41N/A
VSee Health$14.46M0.00-$14.71M-$29.60N/A

7.5% of Aclarion shares are held by institutional investors. Comparatively, 1.0% of VSee Health shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Comparatively, 14.9% of VSee Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

VSee Health has a net margin of -92.36% compared to Aclarion's net margin of -10,215.15%. Aclarion's return on equity of -62.91% beat VSee Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Aclarion-10,215.15% -62.91% -59.33%
VSee Health -92.36%-11,636.34%-68.62%

In the previous week, VSee Health had 2 more articles in the media than Aclarion. MarketBeat recorded 2 mentions for VSee Health and 0 mentions for Aclarion. Aclarion's average media sentiment score of 0.00 beat VSee Health's score of -0.36 indicating that Aclarion is being referred to more favorably in the media.

Company Overall Sentiment
Aclarion Neutral
VSee Health Neutral

Summary

Aclarion beats VSee Health on 12 of the 16 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACON vs. The Competition

MetricAclarionHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.95M$1.92B$7.72B$11.67B
Dividend YieldN/A3.89%2.47%4.53%
P/E Ratio-0.2539.4132.3627.90
Price / Sales48.245.208.285.57
Price / CashN/A15.5120.8521.62
Price / Book0.264.594.443.72
Net Income-$7.23M-$19.09M$3.51B$394.03M
7 Day Performance-15.72%-7.41%-4.69%-4.67%
1 Month Performance-29.10%-7.56%-5.66%-7.21%
1 Year Performance-77.17%-11.73%-1.17%-7.05%

Aclarion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACON
Aclarion
2.4417 of 5 stars
$1.34
-2.2%
$7.50
+459.7%
-78.1%$3.95M$80KN/A11
AIFF
Firefly Neuroscience
0.6285 of 5 stars
$0.91
+3.1%
N/A-45.4%$13.94M$1.14MN/A17
ITOC
Itonic
N/A$1.96
+4.3%
N/AN/A$13.75M$520KN/A7
DRIO
DarioHealth
2.9053 of 5 stars
$1.15
flat
$7.75
+573.9%
-89.0%$12.98M$22.36MN/A165
HCTI
Healthcare Triangle
1.2988 of 5 stars
$3.38
+1.5%
N/A-99.9%$3.05M$13.89MN/A58

Related Companies and Tools


This page (NASDAQ:ACON) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners